Johnson & Johnson Deal History & Licensing Activity
Johnson & Johnson is a large pharma headquartered in US. Over the past three years, Johnson & Johnson has been involved in 20 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 50 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
4
Active Trials
50
Top Modality
Small Molecules
Focus Area
Hematological Malignancies
Johnson & Johnson Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Johnson & Johnson in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| DAC oncology platform/pipeline | Firefly Bio | ADC | Preclinical | acquisition | Jun 8, 2026 |
| HLD-0915 / RIPTAC platform | Halda Therapeutics | Small Molecules | Unknown | acquisition | May 19, 2026 |
| Bota-vec | MeiraGTx | Gene Therapy | Phase 3 | acquisition |
Johnson & Johnson Pipeline Focus
Therapeutic areas and modalities where Johnson & Johnson is most active based on deal history and clinical trial data.
Therapeutic Areas
Johnson & Johnson Strategic Signals
Key indicators of Johnson & Johnson's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Johnson & Johnson Clinical Pipeline
Johnson & Johnson has 50 active clinical trials across 6 development phases.
23
Not Applicable
9
Unknown
5
Phase 4
7
Phase 1
5
Phase 2
1
Phase 3
See How Your Asset Matches Johnson & Johnson's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Johnson & Johnson Licensing & Deal Activity
Johnson & Johnson is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 20 deals over the past three years, Johnson & Johnson ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Johnson & Johnson include Hematological Malignancies (7 deals and trials), Oncology (6 deals and trials), Immunology (6 deals and trials), and Dermatology (6 deals and trials). In terms of modality, Johnson & Johnson has shown particular interest in small molecules, gene therapy, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Johnson & Johnson and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Johnson & Johnson's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.